4 citations
,
February 2025 in “Pharmaceuticals” Voglibose may help treat skin hyperpigmentation safely.
1 citations
,
January 2024 in “Sultan Qaboos University medical journal”
1 citations
,
February 2025 in “South Asian Research Journal of Pharmaceutical Sciences” Eclipta alba flavonoids may help treat diabetes by effectively inhibiting Aldose reductase.
November 2025 in “Frontiers in Veterinary Science” A 1.0% tyrosine diet increases melanin in chicken feathers.
January 2024 in “Wiadomości Lekarskie” Liraglutide with metformin reduces body fat and improves blood sugar control better than metformin and inositol in women with prediabetes.
November 2025 in “Journal of Diabetes Investigation” Dapagliflozin improved blood sugar control in a man with Werner syndrome without side effects.
61 citations
,
January 2015 in “Hormones” Liraglutide caused significant weight loss in some obese women with PCOS, especially those with severe obesity and insulin resistance.
1 citations
,
June 2001 in “Annals of Internal Medicine” Troglitazone increases subcutaneous fat in lipodystrophy patients.
1 citations
,
October 2025 in “Scientific Reports” Sonidegib and vismodegib have different side effects and reporting patterns.
116 citations
,
December 2013 in “European journal of endocrinology” Combining liraglutide and metformin helps obese women with PCOS who didn't lose weight on metformin alone to lose more weight.
3 citations
,
May 2025 in “Frontiers in Pharmacology” Vismodegib can cause muscle spasms, taste changes, hair loss, fatigue, weight loss, and possibly new issues like skin cancer, dehydration, and swallowing problems, needing close monitoring.
25 citations
,
September 2024 in “Cardiovascular Drugs and Therapy” GLP1-RAs may have higher reports of suicidal events and hair loss compared to other diabetes drugs.
March 2026 in “Journal of Pharmaceutical Research” Semaglutide is an effective weekly treatment for obesity, promoting weight loss and improving health, despite some side effects.
February 2025 in “medRxiv (Cold Spring Harbor Laboratory)” GLP-1 agonists may increase the risk of hair loss.
September 2025 in “Wound Repair and Regeneration” GLP-1 receptor agonists may help manage and prevent diabetic foot ulcers.
November 2024 in “Circulation” GLP1-RAs may have higher reports of suicide and hair loss, but no strong evidence links them to these issues.
July 2020 in “Zenodo (CERN European Organization for Nuclear Research)” Pioglitazone combined with metformin or spironolactone improves PCOS symptoms and insulin resistance.
8 citations
,
May 2019 in “Journal of dermatological treatment” Vismodegib is effective for basal cell carcinoma but has severe side effects.
October 2004 in “Australian Prescriber” Agalsidase alfa helps treat Fabry's disease but needs more research for long-term benefits.
58 citations
,
January 2015 in “Journal of the American Academy of Dermatology” Pioglitazone may help treat lichen planopilaris, but more research is needed.
3 citations
,
March 2017 in “Regulatory toxicology and pharmacology” Aleglitazar and its major metabolite are safe enough to proceed to Phase 3 clinical trials.
September 2024 in “Journal of the American Academy of Dermatology” Semaglutide does not significantly increase the risk of hair loss.
3 citations
,
December 2023 in “International Journal of Nanomedicine” Repaglinide-loaded liponiosomal hybrids improve blood sugar control and insulin release better than regular Repaglinide.
7 citations
,
March 2023 in “Lasers in Surgery and Medicine” Ablative fractional laser treatment nearly matches the gene reduction effects of topical vismodegib in skin cancer.
59 citations
,
August 2021 in “Frontiers in Endocrinology” GLP-1 receptor agonists, like Dulaglutide, Liraglutide, and Semaglutide, have potential benefits beyond the pancreas, including neuroprotection, pain suppression, cardiovascular protection, obesity management, and cancer treatment, but there are concerns about pancreatitis and pancreatic cancer risks.
29 citations
,
September 2023 in “Journal of Clinical Medicine” Semaglutide helps obese PCOS patients lose weight and improve health.
July 2023 in “Journal of Clinical Medicine” Tirzepatide might help manage PCOS in obese patients but needs more research to confirm safety and effectiveness.
12 citations
,
December 2018 in “Clinical Ophthalmology” Latanoprostene bunod effectively lowers eye pressure and is better tolerated than other glaucoma medications.
1 citations
,
May 1992 in “Pharmacological Research” Vismodegib effectively treats advanced basal cell carcinoma but requires careful management of serious side effects.